BACKGROUND: An assessment of surgical risk is essential for patient counseling and decision making, and it can provide rationale adjustment for patient populations as health care moves from a fee-for-service to a value-based reimbursement model. The modified Frailty Index (mFI) has been proposed as a risk-stratification tool for radical cystectomy (RC), and the objective of the current study was to validate this potential use of the mFI using an institutional cohort. METHODS: A retrospective review of all patients who underwent RC for bladder cancer was conducted at the authors' institution from 2012 to 2016. In addition to detailed clinicopathologic and treatment parameters, patients were categorized according to the mFI, the Charlson Comorbidity Index (CCI), and the American Society of Anesthesiologists (ASA) classification. Covariates were analyzed to determine associations with 1-month complication rates (according to the Clavien-Dindo system), 3-month readmission rates, hospitalization length, and hospitalization costs. RESULTS: In total, 346 patients were included in the analysis. The overall complication rate was 56.6%, the major (Clavien grade ≥3) complication rate was 19.4%, and the readmission rate was 27.9%. Receiver operating curve analysis demonstrated a weak association of all indices with major complications after RC: the area under the curve was 0.535 (95% confidence interval [CI], 0.460-0.611) for the ASA classification; 0.565 (95% CI, 0.485-0.645) for the CCI score; and 0.551 (95% CI, 0.471-0.631) for the mFI. There were no significant differences in the rate of major complications when stratifying the results according to the mFI, CCI, or ASA class. Length of hospitalization and associated costs were correlated with mFI. CONCLUSIONS: Frailty was not associated with postoperative complications and provided little additional predictive ability over the ASA classification and the CCI score. Further research is required to identify patients who are likely to suffer significant complications after RC. Cancer 2019;125:223-231.
INTRODUCTION
Radical cystectomy (RC) with pelvic lymphadenectomy and intestinal urinary diversion is the mainstay for surgical treatment of muscle-invasive bladder cancer and is often used if intravesical therapy fails to control nonmuscle-invasive disease. [1] [2] [3] Despite significant refinements in surgical techniques, RC remains a highly morbid operation, and greater than one-half of patients experience complications during their hospital stay and after discharge. 4 Preoperative risk assessment has been used for both patient counseling and research purposes. Methods of risk assessment include surrogates of comorbidity, such as the American Society of Anesthesiologists (ASA) Physical Status Classification, 5 the revised Cardiac Risk Index (Lee Criteria), 6 the Charlson Comorbidity Index (CCI), 7 Eastern Cooperative Group performance status, 8 the Elixhauser Index, 9 and the Adult Comorbidity Evaluation-27 (ACE-27). 10 It was reported previously that such tools possess a moderate capacity to predict post-RC outcomes, with a focus on mortality. [11] [12] [13] More recently, there is growing interest in the association of frailty with postsurgical complications. [14] [15] [16] [17] [18] Broadly, frailty is defined as a state of reduced physiologic reserves affecting the capacity to maintain or regain homeostasis after exposure to stressors like surgery, 19 which may compromise postoperative and long-term outcomes. Several tools have been developed to quantify frailty 20, 21 ; however the modified Frailty Index (mFI) has been validated across several surgical specialties. 18, 22, 23 The mFI was originally derived from the Canadian Study of Health and Aging Frailty Index, which incorporated 70 deficits to calculate frailty. 24, 25 The mFI simplified these to a list of 11 select variables that were available in the National Surgical Quality Improvement Program (NSQIP). 23, 26 Chappidi and colleagues used data from the NSQIP to corroborate the association between mFI and complications in patients undergoing RC; patients who had high mFI scores (≥2) had significantly higher rates of complications Cancer January 15, 2019 compared with those who had low mFI scores (<2). 27 More recently, this finding was validated in the same NSQIP data set, with further simplification to only 5 variables, by Sathianathen et al. 28 Beyond the important information that such studies provide for clinical decision making and patient counseling, these findings also are relevant given the anticipated changes from fee-for-service to values-based reimbursement triggered by passage of the Patient Protection and Affordable Care Act of 2010. 29 Although it does not yet affect most urologists, changes by the Centers for Medicaid & Medicare Services in reimbursement schemes loom over the horizon for urologic surgeries. 30 A major criticism of the proposed changes is that they do not clearly define how adjustments will be made for different patient populations. If there is to be adjustment for patient factors in these Centers for Medicaid & Medicare Services benchmarks, then it likely will be by incorporating the aforementioned risk-stratification tools. In the current study, we attempted to validate these risk tools, taking into account detailed baseline, histopathologic, and treatment variables that are not available in databases like the NSQIP.
MATERIALS AND METHODS
We performed a retrospective cohort study at our institution from 2012 to 2016. The study was approved by the University of Texas Southwestern Medical Center Institutional Review Board.
Population
Our study cohort consisted of all patients who underwent RC for bladder cancer. We excluded those patients in whom postoperative complications were not recorded or records were incomplete. In our analysis of readmissions, we excluded those patients who did not receive all oncologic care at our institution to ensure accurate capture of readmissions. RC was performed by 4 different surgeons, using either open or robotic-assisted techniques. The typical pelvic lymphadenectomy template included obturator, internal, and external iliac lymph nodes. Urinary diversion techniques included ileal conduit and Studer-type neobladder based on patient and surgeon preferences.
Variables
Highly detailed baseline clinical and pathologic characteristics were abstracted for each patient, including age, sex, smoking status, body mass index, receipt of neoadjuvant chemotherapy, and pathology. Treatment variables included robotic versus open approach to RC and urinary diversion type.
Several risk-scoring systems were chosen based on prior reports demonstrating their relative performance; the ASA Physical Status Classification, 12 the CCI, 13 and the mFI. 27 All scoring systems were assessed as continuous variables. On the basis of prior studies, the CCI also was grouped into scores of 0 (low), 1 (intermediate), and ≥2 (high). 31 The mFI was categorized by an extended grouping (0, 1, 2, ≥3) or a simplified grouping (low mFI [0 or 1] or high mFI [≥2]). 27 
Outcomes
Postoperative complications were classified according to the Clavien-Dindo system. 32 The primary outcome of interest was to assess the ability of the risk scoring systems to predict major (grade ≥3) complications within 1 month of surgery. Secondary outcomes included readmissions and costs. All readmissions to our hospital or to local hospitals were captured within 3 months of surgery. Costs of RC and hospitalization were captured for each patient through a billing department query. Costs included direct costs of care and excluded indirect costs or charge data.
Statistical Analysis
Means and standard deviations (SD) or median and interquartile range values are reported for normally or nonnormally distributed continuous variables, respectively. The covariates between mFI groups were compared using a 1-way analysis of variance for normally distributed continuous variables, the Kruskal-Wallis H test for ordinal variables, and the chi-square test for categorical values. Receiver operator curve (ROC) analysis was used to evaluate the performance of risk scores as continuous variables for predicting outcomes. Covariates were analyzed using multivariable binomial logistic regression to determine associations with postsurgical outcomes, taking into account age, sex, race, body mass index, receipt of neoadjuvant chemotherapy, urinary diversion type, surgical approach, smoking status, pathology (organconfined vs nonorgan-confined), and either mFI, CCI, or ASA categorization. Statistical analyses were performed using the SPSS Statistics software package (version 22.0; IBM Corporation, Armonk, NY). Two-sided statistical significance was defined as a P value < .05.
RESULTS

Cohort Characteristics
During the study period, 353 patients underwent RC for bladder cancer. Seven patients were excluded because they lacked adequate documentation of postoperative complications, resulting in the inclusion of 346 patients.
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The mean ± SD patient age was 67.7 ± 9.6 years (range, 37-89 years), and 82.4% of patients (n = 285) were men. Of all surgeries, 18.2% were performed using a robotic-assisted technique. Urinary diversion types were ileal conduit in 73.1% of patients (n = 253) and a Studer-type neobladder in 26.9% (n = 93). Overall, 37.6% of patients (n = 130) received neoadjuvant chemotherapy.
Baseline comorbidity data and the risk factors used to calculate mFI and CCI scores are summarized in Table 1 . The most common comorbidities that contributed to the mFI calculations were hypertension (65.3%), diabetes (25.1%), chronic obstructive pulmonary disease (18.2%), and prior cardiac intervention or angina within the past month (12.1%). The most common factors that contributed to the CCI but were not included in the mFI calculation were chronic kidney disease (26.9%) and cerebrovascular disease (6.9%). The mean ± SD mFI score was 1.4 ± 1.2 (range, 0-6); and 22.5% (n = 78), 36.7% (n = 127), 24.0% (n = 83), 10.4% (n = 36), 4% (n = 14), 2% (n = 7), and 0.3% (n = 1) of patients had an mFI score of 0, 1, 2, 3, 4, 5, and 6, respectively. The mean ± SD CCI score was 1.4 ± 1.5 (range, 0-6); and 38.2% (n = 132), 22 .0% (n = 76), and 39.9% (n = 138) of patients had a low, intermediate, and high CCI score, respectively. There was a strong correlation (r) between mFI and CCI scores (r, 0.649; P < .001), a weak correlation between the mFI score and ASA class (r, 0.445; P < .001), and weak correlation between the CCI score and ASA class (r, 0.384; P < .001).
Patient characteristics according to mFI groupings are listed in Table 2 . On average, patients who had higher mFI scores were older, had a higher ASA class, had higher CCI scores, and were less likely to undergo an orthotopic urinary diversion (neobladder). There was no significant difference between mFI groups with respect to sex, race, body mass index, smoking status, receipt of neoadjuvant chemotherapy, surgical approach, or likelihood of nonorgan-confined disease on final pathology (P > .05).
Postoperative Complications
Overall, 56.6% of patients (n = 196) experienced a complication, and 19.4% (n = 67) experienced a major complication (Clavien grade ≥3). There were 7 mortalities (2%) within 1 month of surgery. Table 3 reports overall and major complications according to risk grouping. There were no significant differences in overall complications or major complications according mFI score, CCI grouping, or ASA class.
ROC analysis (Fig. 1) Tables 1A-1D) . Each model identified female gender (hazard ratio, 2.13-2.24; P = .03-.04) and receipt of neoadjuvant chemotherapy (hazard ratio, 1.89-1.97; P = .03-0.4) as independently associated with major complications after RC. None of the indices, including ASA class (P = .47), CCI grouping (P > .05), extended mFI grouping (P > .05), and simple mFI grouping (P = .24), were identified as statistically significant predictors of major postoperative complications.
Hospitalization Length and Costs
The mean ± SD length of hospitalization (LOH) after RC was 8.4 ± 6.7 days, and the mean ± SD direct costs of the operation and hospitalization were $23,810 ± $14,650. Costs and LOH stratified according to measures of frailty are illustrated in detail in Figure 2 and Supporting Tables 2A and 2B . Although the CCI (P = .136) and ASA class (P = .070) were not associated with LOH, higher mFI grouping (by either simple [P = .003] or extended [P = .011] grouping) was correlated with LOH. All comorbidity classification schemes were associated with the cost of operation plus hospitalization (CCI, P = .035; extended mFI grouping, P = .040; simplified mFI grouping, P = .030; and ASA class, P = .040).
Readmissions
In our cohort, 280 patients (80.9%) received all oncologic care at our institution and thus were included in our analysis of readmissions. In total, there were 78 patients (27.9%) who required at least 1 hospitalization within 3 months of discharge after undergoing RC. Twenty-three patients (8.7%) required more than 1 readmission. There was no difference in the rate of readmissions between extended mFI grouping (P = .729), simplified mFI grouping (low mFI, 25.6% vs 31.3%; P = .301), CCI groupings (P = .996), or ASA classification (P = .465) (for details, see Supporting Table 3 ). ROC analysis (Fig. 3) Cancer January 15, 2019
DISCUSSION
Bladder cancer is a disease of the elderly population, and the average age of patients who undergo RC is 68 years. 33 It is well know that this population has a significant rate of coexistent disease, which may affect surgical and oncologic outcomes. The surgical decision-making process and counseling for patients who undergo RC is complex, and an individualized approach is needed to balance the benefits of extirpative surgery and urinary diversion for a life-threatening malignancy and the risk of complications. In addition, proposed changes in reimbursement based on Cancer January 15, 2019 readmission rates for certain disease states. Although it does not yet affect bladder cancer care, the program is expected to expand penalties to additional surgical cases. 34, 35 Understanding the impact of comorbidity on posto perative outcomes could allow for a rational adjustment in such metrics to account for patient factors.
Several risk-scoring tools have been used to study comorbidity. [5] [6] [7] [8] [9] [10] The ASA classification is a general score that was developed in 1941 and was not originally designed as a risk-predictive tool, although it is often used as such. 5 The CCI is a generic scoring system based on weighing various comorbid conditions to predict long-term survival. It is most often used as a research tool rather than in clinical practice. 7 Recently, the concept of patient frailty has been suggested as an accurate predictor of adverse postoperative outcomes in various malignancies. 14, [36] [37] [38] There are multiple purported measures of frailty; however the mFI (a simplification of the Canadian Study of Health and Aging Frailty Index) 25, 26 appears to have gained the most traction in recent literature.
Suskind and colleagues evaluated the mFI using the NSQIP database in over 95,000 patients who underwent 21 different urologic procedures. Those authors reported that a higher frailty score was strongly correlated with minor and major complications in all surgery types, although there was substantial heterogeneity among surgical procedures, and RC had 1 of the lower correlations. 39 Chappidi et al reported outcomes from the same NSQIP cohort specifically among patients who underwent RC. They reported that high mFI scores did not correlate with overall complications but did correlate with severe complications. 27 Also using the NSQIP, Lascano et al performed a similar analysis of several urologic surgeries, including RC and reported that a high mFI score was associated with severe complications and 30-day mortality after adjustment for a limited number of patient variables. It is noteworthy that, although the mFI outperformed the CCI, its performance was inferior to that of the simple ASA classification. 40 Most recently, Sathianathen et al reported on a simplified Frailty Index among older patients (aged ≥65 years) who were undergoing RC. By using the same NSQIP database, those authors observed that patients who had higher simplified Frailty Index scores had a 3-fold increased risk of major postoperative complications. 28 The mFI was developed using the NSQIP database; therefore, the reported studies on the impact of the mFI on RC outcomes using the NSQIP lack external validation. Additional limitations of the NSQIP studies are a follow-up period limited to 30 days, lack of histopathologic staging, and lack of information on neoadjuvant chemotherapy and gastrointestinal complications-1 of Cancer January 15, 2019 the most common complications after RC and urinary diversion. Furthermore, as with all administrative databases, there are concerns about the fidelity of reported data.
Our own study is an attempt to validate the mFI against the CCI and ASA as a predictor of post-RC outcomes. Consistent with the existing literature, we observed that complication rates after RC were high, with an overall 56.6% complication rate and a 19.4% major complication rate. In addition, we observed that the 3-month readmission rate also was high, with 27.9% requiring hospitalization. Unfortunately, we observed little correlation between any of the risk-scoring systems and postoperative outcomes. The AUC of the univariate ROC analysis suggested that the scoring systems were barely more effective than random. Further multivariable analysis reinforced the lack of an association between risk-scoring systems and outcomes. The simple and subjective ASA classification performed similarly to the more complicated CCI and mFI at predicting postoperative outcomes, but all were inaccurate.
The ability to predict complications and institute prevention strategies is important for a surgery that still results in significant morbidity, even when performed by high-volume surgeons in a high-volume facility. Given the importance of predicting complications to patient counseling and decision making, as well as the proposed changes in reimbursement based on surgical outcomes, this should serve as a call for further work to define a more accurate predictive tool. One obvious problem is that most risk-scoring systems do not assign a weighted value to comorbid conditions, depending on the severity of the condition. Research in efforts such as sarcopenia, 41 morphometric age, 42 and serum markers of nutrition status 43 should continue to receive attention. An intriguing possibility is that of leveraging the use of machine learning to better discern which factors or combination of factors might be contributing to adverse postoperative outcomes. Ideally, such a predictive marker(s) would be modifiable. Our current study is subject to the limitations inherent in a retrospective, observational cohort design. Our complication data are limited to 1 month after surgery-however, it has been reported that nearly onehalf of patients will experience a complication after this arbitrary 30-day period. 4 In addition, our institution did not have a set pathway for "enhanced recovery after surgery" throughout the study period, and this may be a confounder. Despite these limitations, we believe the strengths of our study include the ability to capture and adjust for highly detailed clinicopathologic and treatment parameters as well as the inclusion of 3-month readmission data and hospital cost data.
Conclusions
Our attempt to validate the mFI failed to demonstrate its ability at stratifying patients with respect to postoperative complications or readmissions. Furthermore, it did not demonstrate any added value over similarly poor performing, albeit well known, measures, such as ASA class and the CCI score. There is a need for the development of improved risk-assessment tools to predict postoperative outcomes after RC.
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